Compare
Corvus Pharmaceuticals, Inc. vs Aldeyra Therapeutics, Inc. vs Werewolf Therapeutics, Inc. vs Spero Therapeutics, Inc.
| Latest fiscal year | Corvus Pharmaceuticals, Inc. CRVS | Aldeyra Therapeutics, Inc. ALDX | Werewolf Therapeutics, Inc. HOWL | Spero Therapeutics, Inc. SPRO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | $66.80M |
| Revenue growth (YoY) | n/a | n/a | n/a | +39.2% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | 9.5% |
| Net margin | n/a | n/a | n/a | 12.8% |
| Net income | -$15.28M | -$33.85M | -$60.82M | $8.57M |
| EPS (Diluted) | -$0.53 | -$0.56 | -$1.33 | $0.15 |
| Operating cash flow | -$32.80M | -$33.35M | -$60.29M | -$12.62M |
| Free cash flow | -$32.97M | n/a | -$60.29M | n/a |
| Cash & equivalents | $4.58M | $70.04M | $57.05M | $40.27M |
| Total assets | $71.12M | $72.06M | $69.40M | $68.92M |
| Total liabilities | $9.91M | $27.81M | $44.59M | $9.90M |
| Shareholders' equity | $61.20M | $44.25M | $24.80M | $59.02M |
| Return on year-end equity | -25.0% | -76.5% | -245.2% | 14.5% |
| Shares outstanding | 74.70M | 60.16M | 48.60M | 56.41M |
Revenue, most recent five fiscal years
| Fiscal year | Corvus Pharmaceuticals, Inc. | Aldeyra Therapeutics, Inc. | Werewolf Therapeutics, Inc. | Spero Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | n/a | $66.80M Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | n/a | $47.98M Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | n/a | $103.78M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | n/a | $53.51M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | $18.26M Ended 2021-12-31 |